-
Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
Clinical pharmacokinetics 20160101
-
Overview of the new oral anticoagulants: opportunities and challenges.
Arteriosclerosis, thrombosis, and vascular biology 20150501
-
Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Seminars in thrombosis and hemostasis 20150301
-
The role of factor Xa inhibitors in venous thromboembolism treatment.
Vascular health and risk management 20150101
-
Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.
Thrombosis and haemostasis 20121101
-
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20121001
-
Oral direct factor Xa inhibitors.
Circulation research 20120928
-
Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
Thrombosis research 20120901
-
The promise of novel direct oral anticoagulants.
Best practice & research. Clinical haematology 20120901
-
Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
Thrombosis and haemostasis 20120701
-
Long-term benefits of preventing venous thromboembolic events.
Current medical research and opinion 20120601
-
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Critical pathways in cardiology 20120601
-
In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
Thrombosis research 20120401
-
Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation.
Circulation journal : official journal of the Japanese Circulation Society 20120101
-
Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.
Thrombosis and haemostasis 20111201
-
Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system.
Thrombosis and haemostasis 20111201
-
[Current status and future of anti-Xa inhibitors].
Rinsho shinkeigaku = Clinical neurology 20111101
-
The new oral anticoagulants.
Clinical medicine (London, England) 20111001
-
Edoxaban for the prevention of thromboembolic events after surgery.
Drugs of today (Barcelona, Spain : 1998) 20111001
-
[Thromboembolic prophylaxis 2011: is warfarin on the wane?].
Giornale italiano di cardiologia (2006) 20110901
-
Edoxaban: a new oral direct factor xa inhibitor.
Drugs 20110820
-
Edoxaban: pharmacological principles, preclinical and early-phase clinical testing.
Future cardiology 20110701
-
[New anticoagulants in the prevention and treatment of venous thromboembolism].
Orvosi hetilap 20110619
-
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.
Thrombosis and haemostasis 20110601
-
Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.
Thrombosis and haemostasis 20110301
-
Factor Xa and thrombin as targets for new oral anticoagulants.
Thrombosis research 20110101
-
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Annual review of medicine 20110101
-
Edoxaban tosylate.
American journal of cardiovascular drugs : drugs, devices, and other interventions 20110101
-
A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
Journal of thrombosis and haemostasis : JTH 20101101
-
Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Thrombosis research 20101001
-
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
American heart journal 20101001
-
Factor Xa inhibitors: next-generation antithrombotic agents.
Journal of medicinal chemistry 20100909
-
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Thrombosis and haemostasis 20100901
-
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Thrombosis and haemostasis 20100901
-
[Do orally active factor Xa (FXa) inhibitors have potential as innovative new anticoagulants? Future perspective from preclinical data].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100801
-
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
Journal of clinical pharmacology 20100701
-
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Current opinion in cardiology 20100701
-
New anticoagulants for atrial fibrillation.
Seminars in thrombosis and hemostasis 20090701
-
DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.
Journal of thrombosis and haemostasis : JTH 20080901
-
New oral anticoagulants in atrial fibrillation.
European heart journal 20080101
